中国神经再生研究(英文版) ›› 2026, Vol. 21 ›› Issue (10): 4822-4831.doi: 10.4103/NRR.NRR-D-25-01905

• 综述:视神经损伤修复保护与再生 • 上一篇    下一篇

青光眼和年龄相关性视网膜疾病中的视网膜神经胶质细胞:炎症反应、疾病演变和转化前景

  

  • 出版日期:2026-10-15 发布日期:2026-06-12

Retinal glial cells in glaucoma and age-related retinal diseases: Inflammatory responses, disease transitions, and translational perspectives.

Akanksha Salkar1, Viswanthram Palanivel1, Devaraj Basavarajappa1, Benjamin Heng1, Angela Schulz1, Vivek Gupta1, Stuart Graham1, Mehdi Mirzaei1, *, Yuyi You1, 2, *   

  1. 1Macquarie Medical School, Faculty of Human Health and Medical Science, Macquarie University, Sydney, NSW, Australia; 
    2Save Sight Institute, University of Sydney, Sydney, NSW, Australia
  • Online:2026-10-15 Published:2026-06-12
  • Contact: Yuyi You, MD, PhD, yuyi.you@mq.edu.au; Mehdi Mirzaei, PhD, mehdi.mirzaei@mq.edu.au.
  • Supported by:
    The work was supported by the Australian Government Research Training Program (RTP) Scholarship (to AS) and NHMRC Investigator Grant, No. 2034599 (to YY).

摘要:

小胶质细胞、Müller细胞和星形胶质细胞在维持视网膜结构、稳态及神经元功能中发挥着重要的作用。在疾病状态下,这些细胞经历重编程过程,进而引发慢性炎症和神经退行性变。视网膜特有的胶质细胞占据特殊生态位,并与血视网膜屏障密切互作,因而十分脆弱。此次综述总结了胶质细胞活化的机制、共同诱因(包括氧化应激、代谢功能障碍、衰老及全身性炎症),以及重要的信号通路(如核因子κB、丝裂原活化蛋白激酶、Janus激酶/信号转导与转录激活因子、炎性小体及补体系统)。通过比较青光眼、年龄相关性黄斑变性、糖尿病视网膜病变及血管阻塞等疾病的特异性反应,揭示了胶质增生异质性及其对神经元和血管病理的影响。文章还讨论了新兴的人源化平台与蛋白质组学方法,关注其在机制解析和生物标志物发现中的价值。尽管取得进展,但胶质细胞间相互作用机制及以胶质细胞为核心的稳健模型开发仍存在显著空白。尽管取得了这些进展,但对神经胶质细胞-神经胶质细胞通信、状态转换及其与神经退行性疾病的时间关系的理解仍不明确。此外,缺乏专门用于探究胶质细胞生物学的实验模型,这持续制约着转化研究的进展。解决这些挑战对于将神经胶质细胞重新定位为视网膜疾病的核心驱动因素而不是次要反应者至关重要。向以胶质细胞为中心的模型、综合多组学分析和人类相关系统的战略转变有望推进生物标志物的发现,并开发旨在调节胶质细胞功能障碍和保护视力的靶向治疗策略。


https://orcid.org/0000-0002-0175-3018 (Yuyi You); https://orcid.org/0000-0001-8727-4984 (Mehdi Mirzaei)

关键词: 生物标志物, 血视网膜屏障, 细胞因子, 青光眼, 胶质增生, 人源化模型, 神经退行性变, 神经炎症, 氧化应激, 蛋白质组学, 视网膜

Abstract:

Microglia, Müller cells, and astrocytes play a crucial role in maintaining retinal structure, homeostasis, and neuronal function. In disease, they undergo reprogramming that drives chronic inflammation and neurodegeneration. Unique to the retina, these glial cells occupy specialized niches and interact closely with the blood–retinal barrier, creating distinct vulnerabilities. We summarized the glial activation mechanisms, shared triggers, including oxidative stress, metabolic dysfunction, aging, and systemic inflammation, as well as key pathways, such as nuclear factor kappa-B, mitogen-activated protein kinase, Janus kinase/signal transducer and activator of transcription, the inflammasome, and the complement system. Disease-specific responses in glaucoma, age-related macular degeneration, diabetic retinopathy, and vascular occlusions were compared, highlighting the heterogeneity of gliosis and its impact on neuronal and vascular pathology. We also discussed emerging human-derived platforms alongside proteomics approaches, highlighting their utility for mechanistic insights and discovering biomarkers. Despite advances, critical gaps remain in understanding glial–glial interactions and in developing robust models focused on glia. Despite these advances, major gaps remain in our understanding of glial–glial communication, state transitions, and their temporal relationship to neurodegeneration. Moreover, the lack of experimental models explicitly designed to interrogate glial biology continues to limit translational progress. Addressing these challenges will be essential to reposition glial cells as central drivers of retinal disease rather than secondary responders. A strategic shift toward glia-centered models, integrative multi-omics analyses, and human-relevant systems holds promise for advancing biomarker discovery and developing targeted therapeutic strategies that aim to modulate glial dysfunction and preserve vision.

Key words: biomarker, blood–retinal barrier, cytokine, glaucoma, gliosis, humanized model, neurodegeneration, neuroinflammation, oxidative stress, proteomics, retina